AVL9

Across TCGA pan-cancer cohorts, AVL9 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AVL9 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher AVL9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AVL9 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LSCC show a favorable association.

CCRCC, UCEC, and LUAD are the cancer types where AVL9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.588	1.000	.020	23	view →
UCEC	DFS	Quartile	All	0.965	0.708	.009	22	view →
LUAD	DFS	Quartile	All	0.411	0.808	<.001	22	view →
PDAC	DFS	Median	III,IV	0.496	0.874	.009	13	view →
LSCC	OS	Median	All	1.000	0.926	.014	6	view →
GBM	DFS	Quartile	All	0.908	0.680	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AVL9–CCRCC (DFS)

Open the CCRCC breakdown →